Երկիր: Ամերիկայի Միացյալ Նահանգներ
Լեզու: անգլերեն
Աղբյուրը: NLM (National Library of Medicine)
LETROZOLE (UNII: 7LKK855W8I) (LETROZOLE - UNII:7LKK855W8I)
Chartwell RX, LLC
ORAL
PRESCRIPTION DRUG
Letrozole Tablets, USP are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. Letrozole Tablets, USP are indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy. The effectiveness of letrozole in extended adjuvant treatment of early breast cancer is based on an analysis of disease-free survival in patients treated with letrozole for a median of 60 months [ see Clinical Studies ( 14.2 , 14.3 ) ]. Letrozole Tablets, USP are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.Letrozole Tablets, USP are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression fol
Packaged in HDPE bottles with a safety screw cap. Letrozole Tablets, USP 2.5 mg Bottles of 30 tablets................................................NDC 62135-491-30 Bottles of 90 tablets................................................NDC 62135-491-90 Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
LETROZOLE- LETROZOLE TABLET, FILM COATED CHARTWELL RX, LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION LETROZOLE TABLETS THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE LETROZOLE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR LETROZOLE TABLETS. LETROZOLE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 1997 RECENT MAJOR CHANGES Contraindications ( 4) 7/2017 Warnings and Precautions, Embryo-Fetal Toxicity ( 5.6) 7/2017 INDICATIONS AND USAGE Letrozole Tablets, USP are aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1) • Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2) • First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3) DOSAGE AND ADMINISTRATION Letrozole tablets are taken orally without regard to meals ( 2): Recommended dose: 2.5 mg once daily ( 2.1) Patients with cirrhosis or severe hepatic impairment: 2.5 mg every other day ( 2.5, 5.3) DOSAGE FORMS AND STRENGTHS 2.5 mg tablets ( 3) CONTRAINDICATIONS Pregnancy ( 4) Known hypersensitivity to the active substance, or to any of the excipients ( 4) WARNINGS AND PRECAUTIONS Decreases in bone mineral density may occur. Consider bone mineral density monitoring ( 5.1) Increases in total cholesterol may occur. Consider cholesterol monitoring. ( 5.2) Fatigue, dizziness and somnolence may occur. Exercise caution when operating machinery ( 5.4) Embryo-Fetal toxicity: Can cause fetal harm when administered to pregnant women. Obtain a pregnancy test in females of reproductive potential. Advise females of reproductive potential to use effective contraception ( 5.6, 8.1, 8.3) ADVERSE REACTIONS ADVERSE REACTIONS The most common adverse reactions (greater than 20%) were hot flashes, arthralgia; flushing, asthenia, edema, arthralgia, headache, dizziness, hypercholesterolemia, sweat Կարդացեք ամբողջական փաստաթուղթը